Chemomab Therapeutics
CMMB
4 hedge funds and large institutions have $437K invested in Chemomab Therapeutics in 2020 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and 2 closing their positions.
0.02% less ownership
Funds ownership: 0.05% → 0.02% (-0.02%)
20% less funds holding
Funds holding: 5 → 4 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
71% less capital invested
Capital invested by funds: $1.51M → $437K (-$1.07M)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$2.49K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIH
Meitav Investment House
Bene-Beraq,
Israel
|
-$521K |
| 2 |
AIC
AWM Investment Company
New York
|
-$177K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PCM
1
Palisade Capital Management
Fort Lee,
New Jersey
| $291K | – | – | – |
|
|
AIC
2
AWM Investment Company
New York
| $124K | -$177K | -2,419 | -49% |
|
|
PF
3
Phoenix Financial
Givatayim,
Israel
| $20K | – | – | – |
|
|
4
UBS Group
Zurich,
Switzerland
| $2K | +$2.49K | +34 | New |
|
|
MIH
5
Meitav Investment House
Bene-Beraq,
Israel
| – | -$521K | -5,813 | Closed |
|
CMMB Hedge Fund Activity: Q1 2020 in Review
4 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Chemomab Therapeutics (CMMB) for Q1 2020, worth a combined $437K — down 71% from $1.51M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of CMMB and 1 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 0 added.
The largest buyer was UBS Group, opening a new position worth an estimated $2.49K. The largest seller was Meitav Investment House, exiting entirely with an estimated $521K sold.
- 4 institutional investors held Chemomab Therapeutics (CMMB) as of Q1 2020, down from 5 in Q4 2019.
- Funds reported $437K of Chemomab Therapeutics stock for Q1 2020, down 71% quarter-over-quarter.
- 1 fund opened new Chemomab Therapeutics positions in Q1 2020 and 2 closed out, a net change of -1 holder.
- The largest Chemomab Therapeutics buyer in Q1 2020 was UBS Group, an estimated $2.49K added.
- The largest Chemomab Therapeutics seller in Q1 2020 was Meitav Investment House, an estimated $521K sold.
Based on aggregated 13F filings for Q1 2020.